Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs

Arne Staby,Dorte Bjerre Steensgaard,Kim F. Haselmann,Jesper Søndergaard Marino,Christina Bartholdy,Nicoline Videbæk,Ole Schelde,Heidrun Bosch-Traberg,Lotte Touborg Spang,Désirée J. Asgreen
DOI: https://doi.org/10.1007/s11095-020-02817-9
IF: 4.58
2020-06-08
Pharmaceutical Research
Abstract:Manufacturing processes for polypeptide/protein drugs are designed to ensure robust quality, efficacy and safety. Process differences introduced by follow-on manufacturers may result in changes in quality and clinical outcomes. This study investigated the impact of production methods on the stability and impurities of liraglutide and semaglutide drug substances/products, and the potential impact on drug quality, efficacy and safety.
pharmacology & pharmacy,chemistry, multidisciplinary
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: **The impact of manufacturing processes and production scales on the quality, stability, and impurities of polypeptide drugs (especially GLP - 1 analogues liraglutide and semaglutide), and how these factors further affect the efficacy and safety of the drugs**. Specifically, the main objectives of the study are: 1. **Evaluate the impact of production process differences on drug stability**: By comparing the production processes of different suppliers, study the changes in physical and chemical stability and impurity profiles. 2. **Analyze the impact of impurities on immunogenicity**: Use in - silico T - cell epitope prediction methods to assess whether emerging impurities may trigger an immune response. 3. **Immunogenicity assessment in clinical trials**: Through antibody analysis of semaglutide in the SUSTAIN clinical trials, assess its immunogenicity and compare it with liraglutide. 4. **Explore the impact of production processes on drug quality, efficacy, and safety**: Summarize the changes in drug characteristics under different production processes to provide guidance for the development of subsequent versions of drugs. ### Key Findings - **Production processes and scales significantly affect the physical stability of products**: In particular, during large - scale production processes, some batches are more likely to form fibrous precipitates, resulting in a loss of drug content. - **Trace metal ions increase the formation of high - molecular - weight proteins**: The presence of metal ions such as iron and copper will accelerate the formation of high - molecular - weight proteins in liraglutide and semaglutide. - **Different production processes result in different impurity profiles**: Liraglutide produced by synthesis and recombination shows obvious impurity differences among five suppliers. - **New impurities may be immunogenic**: In - silico predictions indicate that emerging impurities may trigger an immune response. - **The immunogenicity of semaglutide is lower than that of liraglutide**: In clinical trials, the frequency and intensity of anti - drug antibody formation in semaglutide are both lower than those in liraglutide. ### Conclusion Differences in production processes do affect the chemical and physical stability and impurity profiles of polypeptide drugs, which in turn may affect the immunogenicity of the drugs. Therefore, subsequent versions of liraglutide and semaglutide, as well as other polypeptide drugs, should be clinically evaluated to ensure their efficacy and safety.